MedTrace Logo

Status Migrainosus - Differentiating Between Responders and Non-responders

NCT03066544 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-08-31

No results posted yet for this study

Summary

The main goal of this study is to determine whether it is possible - in the setup of routine clinical care - to identify in individual patients who are clear responders to drug X, common denominators that are absent in individual patients who are non-responders to the same drug, and vice versa. All currently available knowledge about migraine pathophysiology will be utilized, using as much time as is needed to ask as many questions as are necessary, in an attempt to profile clear responders and clear non-responders.

Conditions

Interventions

DRUG

Bupivacaine

Nerve blocks with bupivacaine will be performed at initial visit

DRUG

Naratriptan Pill

one pill will be administered twice each day for 5 days

DRUG

Dexamethasone

one tablet will be administered twice each day for 3 days

DRUG

Ketorolac

ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit

Sponsors & Collaborators

  • Hartford HealthCare

    lead OTHER

Principal Investigators

  • Brian Grosberg, MD · physician

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-12-31
Completion
2020-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03066544 on ClinicalTrials.gov